Expert Q&A: Virtually In-Person - Enhancing Online Advisory Boards for Peak KOL Engagement

Virtual advisory boards are becoming an essential tool for pharmaceutical companies seeking to engage key opinion leaders (KOLs) efficiently and effectively. By leveraging digital platforms, these virtual boards allow for real-time discussions, global participation and streamlined decision making - without the logistical challenges of in-person meetings.

FirstWord spoke with John Halladay, virtual key account manager at Republic M! Group, about the growing role of virtual advisory boards, their drawbacks and advantages, and how companies can optimise their impact.

Key Questions Answered:

• How have virtual advisory boards changed the way pharmaceutical companies engage with KOLs compared with traditional, in-person meetings?
• What are some potential advantages of virtual advisory boards for enhancing KOL engagement and participation?
• What strategies have been effective during virtual advisory boards for providing value that aligns with KOLs' expectations and interests?
• What methods can be used to maximise engagement during virtual advisory boards?
• What approaches have been beneficial for eliciting engagement from virtual advisory boards that span several weeks?
• What can be done prior to the virtual advisory board to increase engagement during the event?
• What follow-up activities or engagement strategies can help maintain KOL involvement and collaboration after the virtual advisory board concludes?
• What features are important for a virtual platform to meet the specific engagement requirements of an advisory board meeting?
• How can virtual advisory boards incorporate opportunities for spontaneous, off-script conversations while still maintaining a structured agenda?
• How might companies prepare to provide additional materials or information during a virtual advisory board if KOLs request more detailed discussion on specific topics?
• What metrics or feedback mechanisms can be used to assess KOL engagement, and how can companies act on this feedback to enhance future engagement?
• What are the three biggest challenges to KOL engagement in virtual advisory boards?
• What changes do you anticipate in virtual advisory boards to further enhance KOL engagement?
• Do you have any concluding thoughts on the topic of enhancing KOL engagement in the era of virtual advisory boards?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.